Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the reporting period ending on August 14, 2026. The registrant is headquartered in Marseille, France, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a cover document for a press release (Exhibit 99.1) and does not contain embedded financial tables or statements.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. No comparative financial data or operational updates are included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document references a press release dated August 14, 2026, as Exhibit 99.1, which likely contains these details, but the content of that exhibit is not included in the source text.
Key Facts for Investor Verification
- Verify the content of Exhibit 99.1 (Press Release dated August 14, 2026) for specific operational or clinical updates.
- Confirm the company's current cash position and burn rate, as no financial data is present in this filing.
- Review the latest Form 20-F for the most recent audited financial statements.
- Note that the report is signed by Jonathan Dickinson, Chief Executive Officer.